OS Therapies Incorporated — Form 8-K Summary
Business context and reporting period
The 8-K reports executive appointments effective September 29, 2026. OS Therapies appointed Francis (Frank) Knuettel II as Chief Financial Officer and Kerry Clem as Chief Commercial Officer. The company’s former CFO, Christopher P. Acevedo, ceased serving as CFO and will continue as a consultant. The filing was signed October 5, 2026; a related press release was issued October 1.
Financial and compensation details
The filing provides no company revenue, profit, cash flow, margin, debt, or liquidity figures.
- Knuettel’s employment agreement has an initial three-year term and a $300,000 annual base salary, increasing to $360,000 after a defined material transaction occurring more than 30 days after his start date. Qualifying events include specified financings, licensing proceeds, royalty financing, or sale of a priority review voucher.
- Subject to board approval and award terms, Knuettel is to receive options for 750,000 shares and 250,000 restricted stock units (RSUs). Additional performance awards are tied to specified financing, licensing, royalty, voucher-sale, and analyst-coverage milestones.
- Clem’s agreement has an initial three-year term and a $300,000 annual base salary. Subject to board approval and award terms, he is to receive options for 700,000 shares and 200,000 RSUs; further performance awards may be set by the board.
- For both executives, 20% of the initial equity awards vests upon grant, with the remainder vesting quarterly over 12 installments, subject to continued employment.
Changes, terms, and risks
The CFO and CCO appointments add senior financial and commercial leadership. Each agreement provides, in specified qualifying termination circumstances before the third anniversary, 180 days of salary continuation, limited equity vesting acceleration, and potential reimbursement of the company’s share of COBRA premiums. Benefits are conditioned on signing and not revoking a release and complying with post-employment obligations. Both executives are subject to confidentiality, non-competition, and clawback provisions.
The new compensation arrangements create salary and potential equity-related costs and dilution. Knuettel’s salary increase and performance awards depend on defined events; Clem’s additional performance awards remain subject to future board determination. The filing does not quantify the eventual expense or dilution. Employment terms are described in summary and are qualified by the full agreements filed as Exhibits 10.1 and 10.2.
Key facts for investors to verify
- Review Exhibits 10.1 and 10.2 for complete employment terms, definitions, and conditions, including the “material transaction,” Cause, and Good Reason provisions.
- Confirm board approval and final award terms for the stated options and RSUs, and assess potential dilution.
- Monitor whether performance-award milestones are achieved and whether Knuettel’s salary increases under the agreement.
- Check subsequent filings for any updates to executive roles, compensation, or the former CFO’s consulting arrangement.